Have $500? 2 Healthcare Stocks Long-Term Investors Should Buy Right Now

Pfizer is highlighted trading at roughly 9x forward earnings after bolstering its pipeline via acquisitions (Seagen) and buying Metsera’s late-stage obesity candidate to drive future growth. UnitedHealth Group is noted at about 15x forward earnings after operational fixes—plan cuts, price adjustments and AI-driven efficiencies—aimed at restoring growth; its UnitedHealthcare and Optum businesses are cited as a durable moat. Both stocks are recommended as long-term buys for investors willing to hold multi-year positions to capture potential recoveries.

Analysis

Pfizer’s shift toward durable, higher-margin therapeutic franchises changes the earnings cadence from one-off product cycles to multi-year annuities; that reweights its risk from short-term sales volatility to pipeline binary outcomes and biologics manufacturing capacity. Second-order beneficiaries include CMOs, fill-finish specialists and ADC raw-material suppliers — watch order fills and booking schedules over the next 6–18 months as integration and scale reveal margin leverage.

UnitedHealth’s bifurcated model means operational improvements (AI claims automation, plan rationalization) manifest quickly in SG&A and loss-ratio line items, but provider prices and utilization are the levers that determine sustained EPS expansion. Expect visible margin improvement in quarterly reporting within 2–4 quarters if utilization stabilizes; conversely, a surprise uptick in elective care or policy-driven reimbursement changes can erase gains within a single quarter.

The healthcare AI narrative is a non-linear demand accelerator for data-center GPUs — a material, high-margin revenue stream for GPU vendors and a capacity stress test for foundries and memory suppliers. Nvidia is the convex beneficiary of model deployments, while Intel’s optionality lies in lower-cost accelerators and fabs; capex cadence and large enterprise procurement cycles will determine whether this demand is realized in 3–12 months or pushed out to 18+ months.

Key tail risks: regulatory outcomes on pricing and obesity therapeutics, a sustained rebound in medical utilization, and an AI capex pause driven by macro. The consensus buys cyclical troughs as value; the contrarian angle is to treat upcoming quarters as binary catalyst windows — some moves are recoveries, others are re-ratings dependent on clinical/regulatory proofs or payer/provider negotiations.

Key Decisions for Investors

• Long UNH (size 2–4% NAV). Accumulate on pullbacks >3% intraday; horizon 12–24 months. Hedge with 6–9 month 5% OTM puts to cap downside (~10–12% cost). Target 25–40% upside if Optum margin recovery continues; key risk is renewed utilization shock.
• Long PFE (size 2–3% NAV) for 18–36 months to capture pipeline optionality and recurring specialty sales. Use 12-month covered calls 10–15% OTM after initial hold to finance carry and improve yield; stop-loss: 15% on catalyst failure or adverse regulatory news. Expect asymmetric payoff if late-stage assets convert.
• Tactical NVDA exposure via 3–6 month call spreads (small size 0.5–1% NAV) to express near-term healthcare AI deployments while limiting theta/vol risk. Rationale: convex upside from large enterprise GPU orders; downside: capex pullback or deal delays. Close on evidence of multi-hundred-million-dollar ARR wins or quarterly guide-downs.
• Speculative INTC LEAPs (Jan 2028 calls, 1% NAV) to play execution-led manufacturing recovery and lower-cost AI accelerators. Finance by selling short-dated NVDA calls where appropriate (vol arb) to improve carry. Time horizon 18–36 months; execution risk is high but payoff if foundry ramp and product wins materialize.